PMID- 32677504
OWN - NLM
STAT- MEDLINE
DCOM- 20220207
LR  - 20220216
IS  - 1531-1937 (Electronic)
IS  - 0897-1900 (Print)
IS  - 0897-1900 (Linking)
VI  - 35
IP  - 1
DP  - 2022 Feb
TI  - Expanding the Role of the Pharmacist: Immunoglobulin Therapy and Disease 
      Management in Neuromuscular Disorders.
PG  - 106-119
LID - 10.1177/0897190020938212 [doi]
AB  - Immunoglobulin G (IgG) is a commonly used treatment for chronic neuromuscular 
      disorders (NMDs), such as chronic inflammatory demyelinating polyneuropathy and 
      multifocal motor neuropathy. IgG therapy has also shown promise in treating other 
      NMDs including myasthenia gravis, polymyositis, and dermatomyositis. IgG is 
      administered as either intravenous immunoglobulin (IVIg) or subcutaneous 
      immunoglobulin (SCIg), with SCIg use becoming more popular due to the treatment 
      burden associated with IVIg. IVIg requires regular venous access; long infusions 
      (typically 4-6 hours); and can result in systemic adverse events (AEs) for some 
      patients. In contrast, SCIg can be self-administered at home with shorter 
      infusions (approximately 1 hour) and fewer systemic AEs. As patient care shifts 
      toward home-based settings, the role of the pharmacist is paramount in providing 
      a continuation of care and acting as the bridge between patient and clinic. 
      Pharmacists with a good understanding of current recommendations, dosing 
      strategies, and administration routes for IgG therapy are best placed to support 
      patients. The aims of this review are to highlight the evidence supporting IgG 
      therapy in the treatment of NMDs and provide practical information on patient 
      management and IVIg/SCIg dosing in order to guide pharmacists on optimizing 
      clinical outcomes and patient care.
FAU - Tichy, Eric M
AU  - Tichy EM
AUID- ORCID: 0000-0003-1431-0416
AD  - Pharmacy Supply Solutions, Supply Chain Management, Mayo Clinic, Rochester, MN, 
      USA.
FAU - Prosser, Barbara
AU  - Prosser B
AD  - Soleo Health, Sharon Hill, PA, USA.
FAU - Doyle, Drew
AU  - Doyle D
AD  - Soleo Health, Sharon Hill, PA, USA.
LA  - eng
PT  - Journal Article
PT  - Review
DEP - 20200717
PL  - United States
TA  - J Pharm Pract
JT  - Journal of pharmacy practice
JID - 8900945
RN  - 0 (Immunoglobulins, Intravenous)
SB  - IM
MH  - Disease Management
MH  - Humans
MH  - Immunization, Passive
MH  - Immunoglobulins, Intravenous/adverse effects
MH  - *Pharmacists
MH  - *Polyradiculoneuropathy, Chronic Inflammatory Demyelinating
PMC - PMC8822190
OTO - NOTNLM
OT  - disease management
OT  - immunoglobulin therapy
OT  - intravenous immunoglobulin (IVIg)
OT  - neuromuscular disorders
OT  - subcutaneous immunoglobulin (SCIg)
COIS- Declaration of Conflicting Interests: The author(s) declared the following 
      potential conflicts of interest with respect to the research, authorship, and/or 
      publication of this article. E.M.T. reports non-financial support from CSL 
      Behring during the preparation of this review manuscript; personal fees from 
      Shire Pharmaceuticals, personal fees from Grifols Pharmaceuticals, non-financial 
      support from CSL Behring outside of the submitted work. B.P. and D.D. have 
      nothing to disclose.
EDAT- 2020/07/18 06:00
MHDA- 2022/02/08 06:00
PMCR- 2022/02/08
CRDT- 2020/07/18 06:00
PHST- 2020/07/18 06:00 [pubmed]
PHST- 2022/02/08 06:00 [medline]
PHST- 2020/07/18 06:00 [entrez]
PHST- 2022/02/08 00:00 [pmc-release]
AID - 10.1177_0897190020938212 [pii]
AID - 10.1177/0897190020938212 [doi]
PST - ppublish
SO  - J Pharm Pract. 2022 Feb;35(1):106-119. doi: 10.1177/0897190020938212. Epub 2020 
      Jul 17.